European Pharmaceutical Review

JANUARY 11, 2024

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience.

Medicine 102

Medicine Pharmacology Management Side effects 102

Impetus Digital

AUGUST 2, 2024

Looking back at 2023 , AI for drug discovery saw both wins and losses. In theory, this will allow for highly tailored, personalized therapy plans with superior efficacy and minimal side effects. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.

Pharma 95

Pharma Manufacturing Medicine Marketing 95

European Pharmaceutical Review

JULY 18, 2024

1 As they can be highly targeted in their action, they could become the treatment of choice for clinicians and patients due to the reduced risk of side effects. Because ADCs offer a good way to specifically deliver an effective treatment to tumour systems, this could be an improvement on the systemic impact of chemotherapy.

Food and Drug Administration 59

Food and Drug Administration Engineering Pharmacology Side effects 59

European Pharmaceutical Review

SEPTEMBER 22, 2023

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience. 2023 AD/PD Conference.

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

Pharmaceutical Technology

OCTOBER 10, 2022

The company is aiming to enrol the first patient in the ALETTA Phase III trial in Q1 or Q2 of 2023, says Dr. Jan van der Mooren, Freya’s chief medical officer (CMO). The company plans to submit a request for advice from the FDA at the end of this year or the start of 2023, he adds. Neither Addyi nor Vyleesi is approved by the EMA.

Pharmacology 59

Pharmacology Side effects FDA Safety 59